Detailed description page of THPdb

Details of Th1227 which contains 1 entries.

Entry 1
(1) Primary information
ID 1838
ThPP ID Th1227
Therapeutic Peptide/Protein Name Efmoroctocog alfa
Sequence NA view full sequnce in fasta
Functional Classification Ib
Molecular Weight NA
Chemical Formula NA
Isoelectric Point NA
Hydrophobicity NA
Melting Point (℃) NA
Half Life NA
Description Efmoroctocog alfa is a long-acting, fully-recombinant factor VIII Fc fusion protein.
Indication/Disease For the treatment of Haemophilia A.
Pharmacodynamics NA
Mechanism of Action Patients with haemophilia A lack factor VIII, a protein needed for normal clotting of the blood, and as a result, they bleed readily. The active substance in Elocta, efmoroctocog alfa, works in the body in the same way as human factor VIII. It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of bleeding.
Toxicity NA
Metabolism NA
Absorption NA
Volume of Distribution NA
Clearance NA
Categories Antihemophilic Factor
Patents Number NA
Date of Issue NA
Date of Expiry NA
Drug Interaction No interactions of human coagulation factor VIII (rDNA) with other medicinal products have been reported.
Target NA
Information of corresponding available drug in the market
Brand Name ELOCTA
Company NA
Brand Discription Efmoroctocog alfa (recombinant human coagulation factor VIII, Fc fusion protein (rFVIIIFc)) has 1890 amino acids. It is produced by recombinant DNA technology in a human embryonic kidney (HEK) cell line without the addition of any exogenous human- or animal-derived protein in the cell culture process, purification or final formulation.
Prescribed for Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
Chemical Name NA
Formulation 0.6 mmol (or 14 mg) sodium per vial
Physcial Appearance Powder and solvent for solution for injection
Route of Administration Intravenous
Recommended Dosage The calculation of the required dose of recombinant factor VIII Fc is based on the empirical finding that 1 International Unit (IU) factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/dL. The required dose is determined using the following formula: Required units = body weight (kg) x desired factor VIII rise (%) (IU/dL) x 0.5 (IU/kg per IU/dL)
Contraindication Hypersensitivity to the active substance (recombinant human coagulation factor VIII, and/or Fc domain)
Side Effects Hypersensitivity or allergic reactions (which may include swelling of the face, rash, hives, tightness of the chest and difficulty breathing, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hypotension, lethargy, nausea, restlessness, tachycardia) have been observed rarely and may in some cases progress to severe anaphylaxis.
Useful Link http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003964/WC500198642.pdf
PubMed ID 27487799
3-D Structure N.A.

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

(1) Primary information
Entry 1
ID	1838
ThPP ID	Th1227
Therapeutic Peptide/Protein Name	Efmoroctocog alfa
Sequence	NA view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	NA
Chemical Formula	NA
Isoelectric Point	NA
Hydrophobicity	NA
Melting Point (℃)	NA
Half Life	NA
Description	Efmoroctocog alfa is a long-acting, fully-recombinant factor VIII Fc fusion protein.
Indication/Disease	For the treatment of Haemophilia A.
Pharmacodynamics	NA
Mechanism of Action	Patients with haemophilia A lack factor VIII, a protein needed for normal clotting of the blood, and as a result, they bleed readily. The active substance in Elocta, efmoroctocog alfa, works in the body in the same way as human factor VIII. It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of bleeding.
Toxicity	NA
Metabolism	NA
Absorption	NA
Volume of Distribution	NA
Clearance	NA
Categories	Antihemophilic Factor
Patents Number	NA
Date of Issue	NA
Date of Expiry	NA
Drug Interaction	No interactions of human coagulation factor VIII (rDNA) with other medicinal products have been reported.
Target	NA
Information of corresponding available drug in the market
Brand Name	ELOCTA
Company	NA
Brand Discription	Efmoroctocog alfa (recombinant human coagulation factor VIII, Fc fusion protein (rFVIIIFc)) has 1890 amino acids. It is produced by recombinant DNA technology in a human embryonic kidney (HEK) cell line without the addition of any exogenous human- or animal-derived protein in the cell culture process, purification or final formulation.
Prescribed for	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
Chemical Name	NA
Formulation	0.6 mmol (or 14 mg) sodium per vial
Physcial Appearance	Powder and solvent for solution for injection
Route of Administration	Intravenous
Recommended Dosage	The calculation of the required dose of recombinant factor VIII Fc is based on the empirical finding that 1 International Unit (IU) factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/dL. The required dose is determined using the following formula: Required units = body weight (kg) x desired factor VIII rise (%) (IU/dL) x 0.5 (IU/kg per IU/dL)
Contraindication	Hypersensitivity to the active substance (recombinant human coagulation factor VIII, and/or Fc domain)
Side Effects	Hypersensitivity or allergic reactions (which may include swelling of the face, rash, hives, tightness of the chest and difficulty breathing, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hypotension, lethargy, nausea, restlessness, tachycardia) have been observed rarely and may in some cases progress to severe anaphylaxis.
Useful Link	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003964/WC500198642.pdf
PubMed ID	27487799
3-D Structure	N.A.